The 2022/23 MTFM policy was published on 04/03/2022 and a copy can be accessed here.

Key points to note include:

  • The 2021/22 technologies have remained on the policy; these are, PlGF, HeartFlow, GammaCore and SecurAcath.
  • Seven new technologies have been added for 2022/23. Four of these are treatment options for benign prostatic hyperplasia (Urolift, Rezum, Green Light, and Plasma (HOLEP)), with the remaining three being, XprESS sinus dilation system, Thopaz+ portable chest drain, and Spectra Optia (sickle cell).
  • Nationally, it is estimated that implementing the seven new technologies will save the NHS a total of £44m over 5 years.
  • The policy ‘mandates commissioners to fund the MTFM technologies when clinically appropriate’ but does not provide additional funding.
  • MTFM technologies should be procured through the relevant NHS Supply Chain framework, not individually negotiated with suppliers, or reimbursement will not be actioned.
  • AHSN technology leads are expected to develop a suite of implementation support tools to use in product adoption and spread, including a toolkit and business case template.

22/04/2022